Advertisement
Advertisement
STOK
Stoke Therapeutics, Inc. Common Stock
32.71
USDSponsored
+0.78
+2.44%
Aug 07, 15:59 UTC -4
Closed
After-Market
32.81
+0.10
+0.32%
STOK Earnings Reports
Positive Surprise Ratio
STOK beat 18 of 28 last estimates.
64%
Next Report
Tomorrow
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$6.17M
/-$0.81
Implied change from Q1 26 (Revenue/ EPS)
-1.02%
/+2.53%
Implied change from Q2 25 (Revenue/ EPS)
-55.38%
/+102.50%
Stoke Therapeutics, Inc. Common Stock earnings per share and revenue
On May 07, 2026, STOK reported earnings of -0.79 USD per share (EPS) for Q1 26, beating the estimate of -0.84 USD, resulting in a 6.34% surprise. Revenue reached 6.23 million, compared to an expected 6.00 million, with a 3.86% difference. The market reacted with a +0.30% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.81 USD, with revenue projected to reach 6.17 million USD, implying an increase of 2.53% EPS, and decrease of -1.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
FAQ
What were Stoke Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Stoke Therapeutics, Inc. Common Stock reported EPS of -$0.79, beating estimates by 6.34%, and revenue of $6.23M, 3.86% above expectations.
How did the market react to Stoke Therapeutics, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 0.3%, changed from $32.79 before the earnings release to $32.89 the day after.
When is Stoke Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Stoke Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Stoke Therapeutics, Inc. Common Stock is expected to report EPS of -$0.81 and revenue of $6.17M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement